AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16819768
Drug: verapamil 2.5
RxNorm normalized name: verapamil 2.5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 2.5 mg and molsidomine 1 mg
Trial: 16819768
Drug: verapamil 2.5
RxNorm normalized name: verapamil 2.5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 2.5 mg
Trial: 16819768
Drug: verapamil 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 5 mg
Trial: 16819768
Drug: molsidomine 1
RxNorm normalized name: molsidomine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine 1 mg
Trial: 12814763
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (500 mg of elemental calcium as carbonate and 400 IU of vitamin D bid for 12 months)
Trial: 10658002
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids and carbohydrate drink (6 g essential amino acids, 35 g sucrose)
Trial: 8138866
Drug: Blind, placebo‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind, placebo‐controlled medication trial (MT)
Trial: 19716319
Drug: Epalrestat 150
RxNorm normalized name: Epalrestat
DrugBank: Epalrestat (DB15293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epalrestat 150 mg/day (EP group)
Trial: 15808118
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg/day orally for 4 weeks
Trial: 8173242
Drug: VDT work
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VDT work (less than 6 hours daily)
Trial: 8173242
Drug: VDT work
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VDT work (more than 6 hours daily)
Trial: 3555513
Drug: Bardac-22 (didecyl-dimethyl-ammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardac-22 (didecyl-dimethyl-ammonium chloride) in combination with prednicarbate
Trial: 19687490
Drug: TwHF extract,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF extract, 60 mg 3 times daily
Trial: 19687490
Drug: sulfasalazine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfasalazine, 1 g twice daily
Trial: 8325046
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of oral sulodexide (enteric-coated tablets)
Trial: 8325046
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of oral sulodexide (enteric-coated tablets)
Trial: 8325046
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of sulodexide (100 mg/day and 200 mg/day)
Trial: 8325046
Drug: Sulodexide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (oral administration)
Trial: 30439760
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (200 mL daily with Lactobacillus acidophilus La‐5, Bifidobacterium animalis subsp. lactis Bb‐12, Lactobacillus casei subsp. casei Lc‐01)
Trial: 30439760
Drug: Placebo yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yogurt (200 mL daily with Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus)
Trial: 25729066
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (combined superficial and perforating vein surgery)
Trial: 25729066
Drug: Ambulatory compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ambulatory compression therapy
Trial: 18220219
Drug: Biolight therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biolight therapy
Trial: 23967083
Drug: 15% DEET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% DEET lotion
Trial: 21679156
Drug: Cerebrolysin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (10 ml)
Trial: 21679156
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Cerebrolysin and Donepezil
Trial: 16603032
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) plus medication (fluvoxamine)
Trial: 16603032
Drug: Medication (fluvoxamine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (fluvoxamine)
Trial: 22417901
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - 1 g loading dose infused over 10 minutes followed by 1 g intravenous infusion over 8 hours
Trial: 21058191
Drug: High-dose isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isoflavone supplement (450 mg genistein, 300 mg daidzein) daily for 6 months
Trial: 11212979
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5 mg (in ISH subgroup)
Trial: 11212979
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (in ISH subgroup)
Trial: 9371301
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin administered using a validated protocol
Trial: 2701030
Drug: Doxofylline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline 200 mg sachets, administered at a daily dose of 12 mg/kg for 14 days.
Trial: 23929928
Drug: Febuxostat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (80 mg)
Trial: 22178829
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rosiglitazone treatment group
Trial: 16238680
Drug: Atorvastatin or
RxNorm normalized name: atorvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin or simvastatin therapy
Trial: 10210737
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (2 effervescent tablets of 400 mg)
Trial: 10210737
Drug: Paracetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (2 effervescent tablets of 500 mg)
Trial: 10210737
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 effervescent tablets)
Trial: 295279
Drug: Oxazepam 30
RxNorm normalized name: oxazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 30 mg for one week
Trial: 25773354
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Ferric cation (DB13949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 999049 (rFSH) administered subcutaneously at doses of 37.5, 75, 150, 225, or 450 IU
Trial: 25773354
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Ferric cation (DB13949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 999049 (rFSH) administered subcutaneously
Trial: 3202132
Drug: Adenosine triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine triphosphate (ATP) 300 mg daily for 4 weeks
Trial: 3202132
Drug: Betahistine 36
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 36 mg daily for 4 weeks
Trial: 25896182
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (FO) 10 g daily for 12 weeks
Trial: 25896182
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (CO) 10 g daily for 12 weeks
Trial: 16025252
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or Sulphonylurea (non-rosiglitazone group)
Trial: 7746913
Drug: Placebo (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chemotherapy alone)
Trial: 2139286
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine alone (10 micrograms)
Trial: 2139286
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine + hepatitis B immune globulin (HBIg) (10 micrograms + 0.5 ml HBIg)
Trial: 6993109
Drug: Sulphadiazine 225
RxNorm normalized name: Sulphadiazine
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphadiazine 225 mg and Trimethoprim 75 mg (SD/TMP)
Trial: 6993109
Drug: Sulphamethoxazole 400
RxNorm normalized name: Sulphamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphamethoxazole 400 mg and Trimethoprim 80 mg (SM/TMP)
Trial: 23648219
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite administration prior to percutaneous coronary intervention (PCI)
Trial: 23648219
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite administration
Trial: 21663644
Drug: DNA quality
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA quality assessment via gel electrophoresis QC and TaqMan genotyping
Trial: 18604045
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 15/minute)
Trial: 18604045
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 12/minute)
Trial: 14999362
Drug: Ultrahaler (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahaler (3 mg)
Trial: 14999362
Drug: Nebulizer (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer (3 mg)
Trial: 10611198
Drug: Continuous autotransfusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous autotransfusion system of ascites (CATSA) performed for 5 hours at a rate of 100-200 ml/h once a day
Trial: 10611198
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albumin supplement (37.5 g/day)
Trial: 9189783
Drug: Preexercise carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preexercise carbohydrate (CHO) feedings (22.5, 45, or 75 g maltodextrin and dextrose in 473 ml of water)
Trial: 1555806
Drug: Indomethacin gel
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin gel preparation 1
Trial: 1555806
Drug: Indomethacin gel
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin gel preparation 2
Trial: 1555806
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or alternative treatment not specified)
Trial: 26780289
Drug: Relapse to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse to injecting drug use (IDU) after treatment
Trial: 26780289
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of IDU prior to treatment
Trial: 24275909
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), 20 sessions over 5 months
Trial: 24275909
Drug: Psychoanalytic psychotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic psychotherapy, 2 years of weekly sessions
Trial: 22697453
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), n=26
Trial: 16134133
Drug: New drug
RxNorm normalized name: varicella zoster immune globulin (Investigational New Drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drug (low and high dose)
Trial: 11821469
Drug: Preirradiation chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preirradiation chemotherapy (2 cycles of ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine), n = 40
Trial: 11821469
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after irradiation (8 cycles with cisplatin, vincristine, and lomustine), n = 23
Trial: 11821469
Drug: Irradiation (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation (total dose of 35.2 Gy followed by a boost of 20.0 Gy to the primary tumor site), n = 54
Trial: 11821469
Drug: Irradiation (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation (total dose of 54.0 Gy to the tumor region only), n = 7
Trial: 10402369
Drug: L-arginine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine treatment
Trial: 7747293
Drug: 4 ampoules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ampoules (40 mL) of Brazilian Brothrops polyspecific antivenom
Trial: 7747293
Drug: 2 ampoules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ampoules (20 mL) of Brazilian Brothrops polyspecific antivenom
Trial: 2206784
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg verapamil i.v. (8 patients)
Trial: 2206784
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg isosorbide dinitrate sublingually (12 patients)
Trial: 2206784
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (7 patients)
Trial: 24525963
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (vancomycin/cefepime or piperacillin/tazobactam)
Trial: 24525963
Drug: No preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preventive antibiotics (Control)
Trial: 19789884
Drug: iobitridol (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iobitridol (350 mgI/ml)
Trial: 19789884
Drug: iomeprol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol (400 mgI/ml)
Trial: 10811045
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy Programme (MTP)
Trial: 10811045
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment programmes
Trial: 30698049
Drug: Preventive swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive swallowing exercise program (3 weekly supervised sessions of 30 min each and home-based exercises 3 times daily)
Trial: 26667088
Drug: Aspirin-calcitriol-calcium treatment
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin-calcitriol-calcium treatment
Trial: 22934397
Drug: Thermal acupuncture
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal acupuncture needle muscular stimulation therapy, conducted once a week for 4 weeks.
Trial: 22934397
Drug: Celebrex (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celebrex (200 mg, once daily for 4 weeks)
Trial: 20058569
Drug: 20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml/kg of Ringer's lactate
Trial: 20058569
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg of Ringer's lactate
Trial: 12481630
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy with dexamethasone 0.6 mg/kg/day in 3 divided doses for 4 days
Trial: 12481630
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy alone (benzyl penicillin and chloramphenicol for 14 days)
Trial: 10941
Drug: Flurazepam hydrochloride
RxNorm normalized name: Flurazepam Hydrochloride
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurazepam hydrochloride (30 mg)
Trial: 10941
Drug: Pentobarbitone sodium
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbitone sodium (200 mg)
Trial: 28213957
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg kg‐1 b.i.d.
Trial: 28213957
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg kg‐1 t.i.d.
Trial: 21682833
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg added to pioglitazone
Trial: 21682833
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg added to pioglitazone
Trial: 21682833
Drug: Alogliptin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (12.5 or 25 mg) during the 40-week extension
Trial: 11836292
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH therapy at 27 IU (9 mg)/m(2) x wk
Trial: 11836292
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH therapy at 18 IU (6 mg)/m(2) x wk
Trial: 10343539
Drug: Antikeratin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antikeratin antibodies (AKA)
Trial: 10343539
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to human epidermis filaggrin (AFA)
Trial: 10343539
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of APF and AKA
Trial: 10343539
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AFA and AKA
Trial: 8960842
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control (systolic < 150/diastolic < 85 mmHg) with beta blocker (atenolol) or ACE inhibitor (captopril)
Trial: 6819904
Drug: Oral TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRH (20 mg twice daily)
Trial: 6819904
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (10 mg t.d.s.)
Trial: 29029687
Drug: Net‐COPD telemedicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Net‐COPD telemedicine intervention with weekly submission of readings and regular video consultations
Trial: 17318620
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of the same vaccine
Trial: 9787142
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (0.3 mg/kg every 12 hours x 4 doses)
Trial: 7636912
Drug: High Albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Albumin (supplemental albumin to maintain levels 2.5 to 3.5 g/dL)
Trial: 7636912
Drug: Low Albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Albumin (albumin only if levels dropped < 1.5 g/dL)
Trial: 237493
Drug: Alclofenac 3
RxNorm normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alclofenac 3 g
Trial: 237493
Drug: Phenylbutazone 300
RxNorm normalized name: phenylbutazone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 300 mg
Trial: 30859363
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (30 mg/kg/day)
Trial: 30859363
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (60 mg/kg/day)
Trial: 31227681
Drug: Low-dose wide-detector
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose wide-detector scan (experimental group)
Trial: 31227681
Drug: Low-dose helical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose helical scan (low-dose helical group)
Trial: 9029752
Drug: 1-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g oral dose of vigabatrin
Trial: 9029752
Drug: 2-g and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g and 4-g oral doses of vigabatrin